AstraZeneca Wants COPD Label For Symbicort
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly reported trials prove safety and efficacy, company says.
You may also be interested in...
AstraZeneca Submits Symbicort For Asthmatics As Young As Six
Lead investigator touts inhaler's safety profile.
AstraZeneca Submits Symbicort For Asthmatics As Young As Six
Lead investigator touts inhaler's safety profile.
FDA Grants GSK's Advair Broader Use
Top-selling asthma drug cleared for COPD flare-ups.